Drug intelligence / Profile preview

BR1400-3

Development stage: Unknown
Lead developer: Boryung
Modality: Small Molecules
Administration: Oral

Overview

BR1400-3 is an investigational small molecule drug developed by Boryung Pharmaceutical (Boryung Corp.) as part of the BR1400 series for the treatment of essential hypertension and other cardiovascular diseases. It is one of three related compounds (BR1400-1, BR1400-2, and BR1400-3) being evaluated in early-phase clinical trials to assess their pharmacokinetic and pharmacodynamic properties as well as safety in healthy volunteers. The specific mechanism of action and molecular target(s) for BR1400-3 have not been publicly disclosed. Clinical development is currently at Phase 1[1][2][3][5].

Beyond the preview

Go deeper on BR1400-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR1400-3.

Explore the full profile